Helsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR 12 October 2021
Helsinn Group announces oral presentation of data at AACR-NCI- EORTC relating to a potent and highly selective investigational RET inhibitor 7 October 2021
Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQTM (infigratinib) for Patients with Cholangiocarcinoma 29 September 2021
Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD 24 June 2021
Aperte le preiscrizioni al Corso SSS in Tecnica dei sistemi – indirizzo chimico farmaceutica 31 May 2021
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQTM (infigratinib) for Patients with Cholangiocarcinoma 31 May 2021
Linkedin